Page last updated: 2024-12-10

leukotriene d4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280878
CHEMBL ID288943
CHEBI ID28666
SCHEMBL ID12795157
MeSH IDM0027179
PubMed CID6435286
CHEMBL ID1521056
SCHEMBL ID4295683
MeSH IDM0027179

Synonyms (53)

Synonym
CHEBI:28666 ,
(r-(r*,s*-(e,e,z,z)))-n-(s-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinyl)glycine
s-{(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl}-l-cysteinylglycine
leukotriene d(sub 4)
leukotriene d
glycine, n-(s-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinyl)-, (r-(r*,s*-(e,e,z,z)))-
ltd (sub 4)
LMFA03020006
5s-hydroxy-6r-(s-cysteinylglycinyl)-7e,9e,11e,14z-eicosatetraenoic acid
BSPBIO_001368
C05951
leukotriene d4
73836-78-9
NCGC00163399-01
NCGC00163399-02
CHEMBL288943 ,
bdbm50292408
(5s,6r,7e,9e,11z,14z)-6-[(2r)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
unii-5fny4416ue
5fny4416ue ,
LTD ,
ltd4 (leukotriene d4)
glycine, s-((1r,2e,4e,6z,9z)-1-((1s)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraen-1-yl)-l-cysteinyl-
leukotriene d4 [mi]
s-((1r,2e,4e,6z,9z)-1-((1s)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinylglycine
SCHEMBL12795157
YEESKJGWJFYOOK-IJHYULJSSA-N
glycine, s-[(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraen-1-yl]-l-cysteinyl-
(5~{s},6~{r},7~{e},9~{e},11~{z},14~{z})-6-[(2~{r})-2-azanyl-3-(2-hydroxy-2-oxoethylamino)-3-oxidanylidene-propyl]sulfanyl-5-oxidanyl-icosa-7,9,11,14-tetraenoic acid
HMS3402E10
(r-(r*,s*-(e,e,z,z)))-n-(s-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinyl)-glycine
DB11858
Q647917
5s-hydroxy-6r-(s-cysteinylglycinyl)-7e,9e,11z,14z-eicosatetraenoic acid
CS-0059612
HY-113456
AKOS040756242
(5s,6r,7e,9e,11z,14z)-6-({2-amino-2-[(carboxymethyl)carbamoyl]ethyl}sulfanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
gtpl3353
ltd4
NCGC00161277-01
SMP2_000046
s-[(4s,5r,6e,8e,10z,13z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine
BML1-E08
[3h]-ltd4
gtpl3412
[3h]ltd4
SCHEMBL4295683
CHEMBL1521056
DTXSID6040533
LMFA03020077
YEESKJGWJFYOOK-LDDGIIIKSA-N
Q27082010

Research Excerpts

Overview

Leukotriene D4 (LTD4) is a potent biologically active arachidonic acid-derived lipid mediator. It is intimately involved in inflammations and cancers. The direct effect of cysteinyl leukotrienes on fibroblast migration remains unelucidated.

ExcerptReferenceRelevance
"Leukotriene D4 (LTD4) is an important immune inflammatory mediator that is known to be elevated in the mucosa of chronically inflamed intestine and alter nutrient absorption. "( Protein kinase C-mediated phosphorylation of RKIP regulates inhibition of Na-alanine cotransport by leukotriene D(4) in intestinal epithelial cells.
Arthur, S; Sundaram, U, 2014
)
1.85
"Leukotriene D4 (LTD4) is a potent biologically active arachidonic acid-derived lipid mediator that is intimately involved in inflammations and cancers."( Circulating LTD4 in patients with hepatocellular carcinoma.
Guo, D; Jie, S; Li, H; Zhou, Y, 2011
)
1.09
"Leukotriene D4 (LTD4) is a potent mediator in inflammatory processes, but the direct effect of cysteinyl leukotrienes on fibroblast migration remains unelucidated."( Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts.
Desaki, M; Kato, J; Kohyama, T; Nagase, T; Okazaki, H; Rennard, SI; Takizawa, H, 2005
)
2.49
"Leukotriene D4 (LTD4) is a potent bronchoconstrictor and inflammatory mediator in asthma. "( Effect of leukotriene D4 on ciliary activity in human, guinea-pig and rat respiratory mucosa.
Bray, MA; Joki, S; Koskela, T; Nuutinen, J; Saano, V; Toskala, E, 1996
)
2.14
"Leukotriene D4 (LTD4) is a major lipid mediator involved in inflammatory and allergic disorders including bronchial asthma. "( Leukotriene D4 activates mitogen-activated protein kinase through a protein kinase Calpha-Raf-1-dependent pathway in human monocytic leukemia THP-1 cells.
Hoshino, M; Izumi, T; Shimizu, T, 1998
)
3.19

Effects

Leukotriene D4 (LTD4) has been found to induce calcium signalling in the intestinal epithelial cell line Int 407. This action involves the activation of both different GTP-binding proteins (G-proteins) and phospholipase C of the gamma-subtype (PLC-gamma)

ExcerptReferenceRelevance
"Leukotriene D4 (LTD4) has been found to induce calcium signalling in the intestinal epithelial cell line Int 407, and this action involves the activation of both different GTP-binding proteins (G-proteins) and phospholipase C of the gamma-subtype (PLC-gamma). "( The regulation of leukotriene D4-induced calcium influx in human epithelial cells involves protein tyrosine phosphorylation.
Engström, M; Grönroos, E; Schippert, A; Sjölander, A, 1995
)
2.07
"Leukotriene D4-(LTD4) has been reported to cause tachykinin release from airway sensory nerves. "( Involvement of endogenous tachykinins in LTD4-induced airway responses.
Ichinose, M; Ishikawa, J; Kageyama, N; Miura, M; Sasaki, Y; Shirato, K; Tomaki, M; Yamauchi, H, 1996
)
1.74

Actions

ExcerptReferenceRelevance
"Leukotriene D4 did not cause synaptic transmitter release through ganglionic stimulation, because its contractile effect was tetrodotoxin insensitive, and did not contribute to noncholinergic excitation through stimulation of neurokinin A release, as the neurokinin2 receptor antagonist, MEN 10,376, did not alter the response to leukotriene D4."( Neural control of mouse small intestinal longitudinal muscle: interactions with inflammatory mediators.
Finkelman, FD; Goldhill, JM; Morris, SC; Shea-Donohue, T, 1995
)
1.01

Toxicity

ExcerptReferenceRelevance
"To explore whether the proinflammatory products of the 5-lipoxygenase (5-LOX) pathway are involved in microglia-mediated toxicity toward neuronal cells, we evaluated the effects of 5-LOX inhibitors using an in vitro assay system where human neuronal SH-SY5Y cells are exposed to toxic secretions from THP-1 monocytic cells or human microglia."( Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP.
Klegeris, A; McGeer, PL, 2003
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacodynamic effect was assessed by testing the ability of BAY x 7195 aerosol to inhibit leukotriene-D4 (LTD4) induced bronchoconstriction in healthy volunteers."( Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers.
Heinig, R; Kuhlmann, J; Wensing, G, 1996
)
0.29
" In general, after both single and repeated doses, there were related increases in the corresponding Cmax and AUC with a rise in dose, although the increase was diminished at doses above 450 mg."( The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers.
Allen, E; Brocks, DR; Dennis, MJ; Doyle, E; Georgiou, P; Stelman, G; Upward, JW; Wyld, P, 1996
)
0.29
" This method has utility in evaluating the pharmacodynamic action of either LTB(4) receptor antagonists or immune cell modulators in effecting CD11b integrin expression and granulocyte activation in human subjects administered such drugs."( Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation.
Carpenter, DC; Davis, HM; Griswold, DE; Hynicka, WP; Stahl, JM; Zhang, W, 2000
)
0.31
"The influence of dose and food on the pharmacokinetic profile of orally administered verlukast, a leukotriene D4 receptor antagonist, was investigated in 12 healthy male volunteers."( Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.
Bjornsson, TD; Hsieh, JY; Lin, CC; Margolskee, DJ; Rogers, JD; Schwartz, JI; Williams, VC, 1993
)
0.76

Compound-Compound Interactions

ExcerptReferenceRelevance
"To examine the clinical typing and individualized treatment approach for allergic rhinitis and to determine the optimal treatment method for this disease using various drug combination therapies."( Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels.
Chen, F; Li, G; Shen, C; Wang, H; Wen, Z; Zhang, X,
)
0.34
"Clinical symptom evaluation combined with experimental detection of histamine and leukotriene levels can be an objective and accurate method to clinically classify the allergic rhinitis types."( Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels.
Chen, F; Li, G; Shen, C; Wang, H; Wen, Z; Zhang, X,
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic data in the rat demonstrated approximately 100% bioavailability of the agent."( Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
Caselli, G; Ferrari, F; Makovec, F; Mennuni, L; Zanelli, T, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Dose-response comparison of RG 7152 with the tetrazole-substituted leukotriene D4 antagonist LY 171883 to be slightly more potent than RG 7152."( Induction of peroxisomal enzymes by a tetrazole-substituted 2-quinolinylmethoxy leukotriene D4 antagonist.
Groth-Watson, A; Kelley, M; Knoble, D; Kornbrust, D, 1994
)
0.75
" Bronchodilator activity was assessed by spirometry before and at multiple time points after dosing for eight hours."( Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults.
Feiss, G; Nelson, HS; Paull, BR; Smith, JA; Tobey, RE; Welch, MJ, 1994
)
0.29
" Dose-response curves for LTD4 (12-240 ng/min) on coronary flow were shifted to the left in rats with permanent coronary occlusion for 8 wk or with coronary occlusion for 30 or 60 min and reperfusion for 4 wk."( Effects of LTD4 and its specific antagonist L-660,711 in isolated rat hearts with chronic myocardial infarction.
Ertl, G; Gaudron, P; Han, H; Hu, K; Neubauer, S; Tian, R, 1994
)
0.29
" The same general protocol was used for all studies, except that the dosage and time of TYB-2285 treatment was varied."( Effect of TYB-2285 on antigen-induced airway responses in sheep.
Abraham, WM; Ahmed, A; Cortes, A; Sielczak, M; Wantanabe, A, 1996
)
0.29
" In contrast, SKF 104353 effectively antagonized the LTC4-induced contractions in isolated human bronchial smooth muscle preparations, shifting the agonist dose-response curve to the right by some 3 log-fold in this tissue."( Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism.
Bochner, BS; Pedersen, KE; Undem, BJ, 1997
)
0.3
" In all tissues, LTD4 increased CBF showing a bell-shaped dose-response curve."( Effect of leukotriene D4 on ciliary activity in human, guinea-pig and rat respiratory mucosa.
Bray, MA; Joki, S; Koskela, T; Nuutinen, J; Saano, V; Toskala, E, 1996
)
0.7
"5 hours after dosing compared with placebo."( Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.
Barnes, NC; Compton, CH; Dennis, M; Georgiou, P; Howland, K; O'Shaughnessy, TC, 1997
)
0.53
" FK224 (10(-6) M and 10(-5) M, respectively) significantly inhibited NKA-induced contraction and 10(-5) M FK224 shifted the dose-response curve to more than one log unit higher concentration."( Tachykinin antagonist FK224 inhibits neurokinin A-, substance P- and capsaicin-induced human bronchial contraction.
Ando, M; Fujii, K; Goto, E; Hamamoto, J; Hirata, N; Honda, I; Iwagoe, H; Kohrogi, H; Yamaguchi, T, 1997
)
0.3
" Blood samples were collected two hours after dosing to determine plasma concentrations of zafirlukast."( A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
Hanby, LA; Lavins, BJ; Simonson, SG; Smith, LJ, 1998
)
0.3
" For poorly soluble drugs, the existing mechanisms are limited to osmosis and matrix erosion, that are commonly observed in single unit matrix dosage forms."( Release performance of a poorly soluble drug from a novel, Eudragit-based multi-unit erosion matrix.
Kislalioglu, MS; Malick, AW; Mehta, KA; Phuapradit, W; Shah, NH, 2001
)
0.31
"L-708,738 was bioavailable after oral administration and sustained concentrations in plasma during the dosing period that exceeded in vitro efficacy values."( Comparison of effects of dexamethasone and the leukotriene D4 receptor antagonist L-708,738 on lung function and airway cytologic findings in horses with recurrent airway obstruction.
Charette, L; Guay, D; Hickey, GJ; Lavoie, JP; Léguillette, R; Murphy, T; Pasloske, K; Sawyer, N, 2002
)
0.57
"1 microM), or the cyclooxygenase enzyme (COX) inhibitor diclofenac (10 microM) each caused a parallel and rightward shift in the dose-response relation for OVA, providing evidence for contributions of histamine, cysteinyl-leukotrienes, and COX products to the OVA-induced bronchoconstriction in the IPL."( Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
Dahlén, SE; Låstbom, L; Ryrfeldt, A; Sundström, E, 2003
)
0.32
" The antiinflammatory dose-response curve of loratadine was shifted to the left when studied in combination with montelukast (0."( Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat.
Hunter, JC; Jia, Y; Jimenez, J; Lieber, G; McLeod, RL, 2010
)
0.36
" Airway responsiveness was assessed based on the cumulative dosage causing a 20% fall in FEV(1) (PD(20)FEV(1)-LTD4) and was expressed as (median, interquartile range)."( Leukotriene D4 bronchial provocation test: methodology and diagnostic value.
An, J; Gao, Y; Guan, W; Jiang, C; Liu, W; Yu, X; Zheng, J, 2012
)
1.82
"Response-dose ratio (RDR) and cumulative provocative dosage (PD) are useful indices reflecting airway responsiveness in asthma."( Response--dose ratio is a surrogate of cumulative provocative dosage for bronchial provocation tests in asthma.
An, JY; Gao, Y; Guan, WJ; Jiang, CY; Liu, WT; Shi, X; Xie, YQ; Yu, XX; Zheng, JP; Zhu, Z, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
bronchoconstrictor agentA drug which causes a narrowing of the lumen of a bronchus or bronchiole.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
leukotrieneAny icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (63)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Leukotrienes (LT) and Eoxins (EX)1329
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Fc Epsilon Receptor I Signaling in Mast Cells4211
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Disease1278231
Infectious disease89579
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Eicosanoid metabolism via lipooxygenases (LOX)040
Leishmania infection6626
Leishmania parasite growth and survival2018
Anti-inflammatory response favouring Leishmania parasite infection2018
LTC4-CYSLTR mediated IL4 production57
Prostaglandin and leukotriene metabolism in senescence619
Leukotriene metabolic pathway219
Arachidonic acid (AA, ARA) oxylipin metabolism076
Parasitic Infection Pathways6626
Folic acid network070
Eicosanoid metabolism via lipoxygenases (LOX)040
Selenium micronutrient network095
Eicosanoid synthesis026
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency26.67950.531815.435837.6858AID504845
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00350.003245.467312,589.2998AID2517
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.600310.0000AID751668
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.00030.00030.86666.6900AID751668
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.630610.0000AID751668
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.00030.00030.68056.6900AID751668
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00070.00061.525710.0000AID751668
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.00030.00030.70716.6900AID751668
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.747210.0000AID751668
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.00030.00030.81966.6900AID751668
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.741110.0000AID751668
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.00030.00030.70726.6900AID751668
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)5.48002.62005.97679.8300AID681600
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.741110.0000AID751668
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.00030.00030.70726.6900AID751668
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.00070.00071.741110.0000AID751668
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.00030.00030.70726.6900AID751668
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)0.00390.00030.948710.0000AID566263; AID751668
Cysteinyl leukotriene receptor 1Homo sapiens (human)Ki0.00040.00021.56248.8720AID338157; AID751668
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cysteinyl leukotriene receptor 2Homo sapiens (human)EC50 (µMol)0.00440.00440.10210.2930AID1877362
Cysteinyl leukotriene receptor 1Homo sapiens (human)EC50 (µMol)0.00090.00090.05500.1040AID1877361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Km1.50001.50004.34206.9000AID678989
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID566263Inhibition of human leukotriene D4 receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID338194Displacement of [3H]LTD4 from LTD4 receptor assessed as specific binding relative to total binding1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID338157Displacement of [3H]LTD4 from LTD4 receptor1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID751668Displacement of [3H]LTD4 from human recombinant cysteinyl leukotriene receptor 1 expressed in CHOK1 cells after 30 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID75949Compound was evaluated for its activity in vitro with use of isolated guinea pig tracheal spiral strips in the presence of L-cysteine (3 mM)1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Chemically stable homocinnamyl analogues of the leukotrienes: synthesis and preliminary biological evaluation.
AID75945Compound was evaluated for its activity in vitro with use of isolated guinea pig tracheal spiral strips in the presence (control )1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Chemically stable homocinnamyl analogues of the leukotrienes: synthesis and preliminary biological evaluation.
AID681351TP_TRANSPORTER: uptake in membrane vesicle from MRP1-expressing HeLa cells1996Cancer research, Mar-01, Volume: 56, Issue:5
Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump.
AID1877361Agonist activity at human CysLT1 receptor2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.
AID678989TP_TRANSPORTER: uptake in liver plasma membrane vesicles of Wistar rat1990The Journal of biological chemistry, Nov-05, Volume: 265, Issue:31
ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates.
AID77522Compound was tested for FPL-55712 sensitivity in the absence of metabolic inhibitors; Yes1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Chemically stable homocinnamyl analogues of the leukotrienes: synthesis and preliminary biological evaluation.
AID1877362Agonist activity at human CysLT2 receptor2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.
AID681600TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells2001Molecular pharmacology, May, Volume: 59, Issue:5
Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2.
AID751732Displacement of [3H]LTD4 from human recombinant cysteinyl leukotriene receptor 1 expressed in CHOK1 cells at 10 uM after 30 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID370722Activity at MRP1 in human HeLa T5 cells assessed as ATP-dependent drug transport at 50 nM measured per mg of protein2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1).
AID1346031Human CysLT1 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2011Molecular pharmacology, Feb, Volume: 79, Issue:2
Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
AID1346914Human GPR17 (Class A Orphans)2006The EMBO journal, Oct-04, Volume: 25, Issue:19
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)1998Molecular pharmacology, Apr, Volume: 53, Issue:4
Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma.
AID1346857Mouse GPR17 (Class A Orphans)2008PloS one, , Volume: 3, Issue:10
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2011FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Oct, Volume: 25, Issue:10
Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2000Biochemical and biophysical research communications, Aug-02, Volume: 274, Issue:2
The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1999Nature, Jun-24, Volume: 399, Issue:6738
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000Biochemical and biophysical research communications, Aug-02, Volume: 274, Issue:2
The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000The Journal of biological chemistry, Sep-29, Volume: 275, Issue:39
Characterization of the human cysteinyl leukotriene 2 receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2007Pharmacogenetics and genomics, Jul, Volume: 17, Issue:7
A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2011FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Oct, Volume: 25, Issue:10
Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2003Prostaglandins & other lipid mediators, Jul, Volume: 71, Issue:3-4
Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2005Journal of cell science, Dec-01, Volume: 118, Issue:Pt 23
CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1998British journal of pharmacology, Feb, Volume: 123, Issue:3
Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro.
AID1346031Human CysLT1 receptor (Leukotriene receptors)1998Molecular pharmacology, Apr, Volume: 53, Issue:4
Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (682)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.15)18.7374
1990's287 (42.08)18.2507
2000's282 (41.35)29.6817
2010's98 (14.37)24.3611
2020's14 (2.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.22 (24.57)
Research Supply Index6.61 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index41.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials42 (6.03%)5.53%
Trials0 (0.00%)5.53%
Reviews32 (4.59%)6.00%
Reviews0 (0.00%)6.00%
Case Studies2 (0.29%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other621 (89.10%)84.16%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]